Cargando…
Addressing the needs of Canadians with rare diseases: an evaluation of orphan drug incentives
It is uncertain whether a Canadian orphan drug policy, similar to those used in the US and EU, will be given further consideration. The justification for having an orphan drug policy is initially discussed, with this article proceeding on the basis that morality and a commitment to equality validate...
Autor principal: | Harris, Emily |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534751/ https://www.ncbi.nlm.nih.gov/pubmed/31143457 http://dx.doi.org/10.1093/jlb/lsy019 |
Ejemplares similares
-
Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2021) -
Incentives for orphan drug research and development in the United States
por: Seoane-Vazquez, Enrique, et al.
Publicado: (2008) -
Orphan drug incentives in the pharmacogenomic context: policy responses in the US and Canada
por: Gibson, Shannon, et al.
Publicado: (2015) -
Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?
por: Rodriguez-Monguio, R., et al.
Publicado: (2017) -
Orphan drug incentives in the pharmacogenomic context: policy responses in the USA and Canada
por: Herder, Matthew
Publicado: (2016)